Neither BPC-157 nor TB-500 holds FDA approval for any medical indication. The FDA Approved Drugs database and regulatory authorities explicitly state that these peptides are unapproved for therapeutic use in the United States. The 2026 Category 1 reclassification only permits compounding under physician oversight, which is not equivalent to FDA approval.
Large-scale, randomized controlled human clinical trials have not been completed for either peptide. Existing human evidence is limited to small, uncontrolled pilot studies, and the majority of research remains preclinical or animal-based, as confirmed by PubMed and ClinicalTrials.gov listings.
The FDA and NIH emphasize that, without robust clinical evidence and formal approval, these peptides should not be marketed as proven therapies. Their legal use is narrowly restricted, and claims of FDA approval or broad scientific validation are unsupported by current evidence.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.